Weight is a risk factor for treatment mortality in AML

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Research

Background:

• Acute myeloid leukaemia (AML) is a significant health concern in children.
• Nutritional status, specifically body mass index (BMI), can influence treatment outcomes in various cancers.
• The impact of weight deviations on treatment complications in pediatric AML requires further elucidation.

Purpose of the Study:

• To investigate the association between body weight status (underweight, normal weight, overweight) and treatment-related complications in pediatric patients diagnosed with acute myeloid leukaemia.
• To determine if weight category is an independent risk factor for adverse events during AML therapy.

Main Methods:

• Retrospective cohort study design.
• Analysis of clinical data from pediatric patients with newly diagnosed AML.
• Categorization of patients based on BMI percentiles into underweight, normal weight, and overweight groups.
• Statistical analysis to compare the incidence of treatment-related complications across weight categories.

Main Results:

• Overweight and underweight pediatric AML patients exhibited a statistically significant higher incidence of treatment-related complications compared to normal weight counterparts.
• Specific complications such as infections and prolonged hospitalizations were more frequent in non-normal weight groups.
• Weight status emerged as a significant predictor of adverse treatment events.

Conclusions:

• Body weight status is a critical factor influencing treatment complication rates in pediatric acute myeloid leukaemia.
• Clinical management strategies for pediatric AML should consider nutritional status and weight management.
• Further research into optimizing treatment protocols based on weight for improved pediatric AML outcomes is warranted.